Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study - Summary - MDSpire

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • By

  • Zhong Wang

  • Yimin Zhang

  • Feng Yao

  • Jinxin Li

  • Chenyuan Li

  • Shichong Liao

  • June 18, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of T-DM1 versus trastuzumab plus pertuzumab in adjuvant treatment of HER2-positive breast cancer patients with residual invasive disease after neoadjuvant therapy, emphasizing the comparative aspect.

Key Findings:
  • Clarify the clinical significance of exploratory subgroup analyses.
Interpretation:

Highlight the implications of findings for clinical practice more explicitly.

Limitations:
  • Add limitations related to potential confounding factors in a retrospective study.
Conclusion:

Reiterate the importance of findings in the context of existing treatments.

Original Source(s)

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • by Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao

  • June 18, 2026

Related Content

Temporal dynamics and determinants of early recurrence after curative resection for stage I-III rectal cancer: integrated analyses of hazard function, survival, and competing risks

Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment

2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min